Skip to main content

and
  1. Article

    Open Access

    Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study

    Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbatio...

    Tara F. Carr, Wendy C. Moore, Monica Kraft, Guy Brusselle in Advances in Therapy (2024)

  2. Article

    Open Access

    Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review

    Patients with uncontrolled, allergic severe asthma may be prescribed biologic therapies to reduce exacerbations and improve disease control. Randomized controlled trials (RCTs) of these therapies have differed...

    Jonathan A. Bernstein, Jean-Pierre Llanos, Gillian Hunter in Advances in Therapy (2023)

  3. Article

    Open Access

    Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study

    Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV1) ...

    Andrew Menzies-Gow, Christopher S. Ambrose, Gene Colice in Advances in Therapy (2023)

  4. Article

    Open Access

    Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review

    Randomized controlled trials (RCTs) of biologics in patients with severe, uncontrolled asthma have shown differential results by baseline blood eosinophil count (BEC). In the absence of head-to-head trials, we...

    Stephanie Korn, Bill Cook, Lisa J. Simpson, Jean-Pierre Llanos in Advances in Therapy (2023)

  5. Article

    Open Access

    Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

    Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosi...

    Hector Ortega, Catherine Lemiere in Allergy, Asthma & Clinical Immunology (2019)

  6. Article

    Open Access

    Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab

    Previous studies showed that mepolizumab significantly reduces exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma. However, early studies reported inconsistent effects on lun...

    Hector Ortega, Andrew Menzies-Gow, Jean-Pierre Llanos, Mark Forshag in Advances in Therapy (2018)